【摘要】 目的 :卡铂、顺铂合用治疗肺癌临床疗效观察。方法 :122例Ⅲ～Ⅳ期肺癌病人随机分为三组 ,行联合化疗 ,每4周重复一疗程。结果 :DDP +VP1640例 ,CR +PR18例 ,有效率45.00 % ,Ⅱ度以上呕吐发生率87.50% ,Ⅱ度以上白细胞下降率37.50% ;CBP +VP₁640例 ,有效率45.00% ,Ⅱ度以上白细胞下降率90.00% ;1/2DDP+1/2CBP +VP₁642例 ,CR +PR16例 ,有效率38.13% ,Ⅱ度以上呕吐发生率47.62% ,Ⅱ度以上白细胞下降率42.85%。结论 :卡铂、顺铂合用 ,剂量减半可以不影响疗效 ,但能明显减少毒性反应。更多还原

【Abstract】 Objective:To investigate the therapeutic effect of cisplatin plus carboplatin in lung cancer treatment.Method:122 cases of advanced lung cancer were randomly divided into three groups.Patients of each group were treated with carboplatin or cisplatin or both plus etoposide respectivly.Rsults:For the 40 cases of cisplatin plus etoposide(vp 16),the CR+PR rate was 45.00%,vomiting over grade Ⅱ 87.50%,leukopenia over grade Ⅱ 37.50%;for 40 cases of carboplatin plus etoposide,the CR+PR rate was 45.00%,leukopenia over grade Ⅱ 90%;for the 42 cases of half dosage cisplatin and the half dosage carboplatin plus etoposide,the CR+PR rate was 38.13%,vomiting over grade Ⅱ 47.62%,leukopenia over grade Ⅱ 42.85%.Conclusion:The half dosage of cisplatin plus carboplatin has no influence on therapeutic effects,but will reduce toxic reaction (vomiting and leukopenia).更多还原